<a href="https://laohu8.com/S/HCWB">HCW Biologics Inc.</a> Announces $5 Million At-The-Market Follow-On Offering Under NASDAQ Rules
HCW Biologics Inc., a clinical-stage biopharmaceutical company, has announced the pricing of its follow-on offering, raising approximately $5.0 million through the sale of 671,140 units at $7.45 each. Each unit consists of one share of common stock and two warrants for additional shares, with the warrants exercisable immediately and expiring in five years. The proceeds will support preclinical and clinical development, business development, patent portfolio expansion, research, and general corporate purposes. Maxim Group LLC is serving as the sole placement agent for the offering.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-082005), on June 05, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。